1,3-dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors

Publisher Website
Google Scholar
Abstract
The structure–activity relationships (SAR) of alkylxanthine derivatives as antagonists at the recombinant human adenosine receptors were explored in order to identify selective antagonists of A2B receptors. The effects of lengthening alkyl substituents from methyl to butyl at 1‐ and 3‐positions and additional substitution at the 7‐ and 8‐positions were probed. Ki values, determined in competition binding in membranes of HEK‐293 cells expressing A2B receptors using 125I‐ABOPX (125I‐3‐(4‐amino‐3‐iodobenzyl)‐8‐(phenyl‐4‐oxyacetate)‐1‐propylxanthine), were approximately 10 to 100 nM for 8‐phenylxanthine functionalized congeners. Xanthines containing 8‐aryl, 8‐alkyl, and 8‐cycloalkyl substituents, derivatives of XCC (8‐[4‐[[[carboxy]methyl]oxy]phenyl]‐1,3‐dipropylxanthine) and XAC (8‐[4‐[[[[(2‐aminoethyl)amino]carbonyl]methyl]‐oxy]phenyl]‐1,3‐dipropylxanthine), containing various ester and amide groups, including L‐ and D‐amino acid conjugates, were included. Enprofylline was 2‐fold more potent than theophylline in A2B receptor binding, and the 2‐thio modification was not tolerated. Among the most potent derivatives examined were XCC, its hydrazide and aminoethyl and fluoroethyl amide derivatives, XAC, N‐hydroxyethyl‐XAC, and the L‐citrulline and D‐p‐aminophenylalanine conjugates of XAC. An N‐hydroxysuccinimide ester of XCC (XCC‐NHS, MRS 1204) bound to A2B receptors with a Ki of 9.75 nM and was the most selective (at least 20‐fold) in this series. In a functional assay of recombinant human A2B receptors, four of these potent xanthines were shown to fully antagonize the effects of NECA‐induced stimulation of cyclic AMP accumulation. Drug Dev. Res. 47:45–53, 1999. Published 1999 Wiley‐Liss, Inc. This article is a US Government work and, as such, is in the public domain in the United States of America.

This publication has 40 references indexed in Scilit: